Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Moreau, Philippe [1 ]
Kumar, Shaji [2 ]
Boccia, Ralph [3 ]
Iida, Shinsuke [4 ]
Goldschmidt, Hartmut [5 ]
Cocks, Kim [6 ]
Zahlten-Kumeli, Anita [7 ]
Yucel, Emre [7 ]
Panjabi, Sumeet [7 ]
Dimopoulos, Meletios [8 ]
机构：
[1] Univ Hosp Hotel Dieu, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] KCStats Consultancy, Leeds, W Yorkshire, England
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
multiple myeloma; carfilzomib; once-weekly; patient-reported outcomes; quality of life;
D O I：
10.1016/j.clml.2018.07.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-138
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [41] Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
    Richard, Shambavi
    Chari, Ajai
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Kryachok, Irina
    Dimopoulos, Meletios A.
    Pylypenko, Halyna
    Auner, Holger W.
    Leleu, Xavier
    Doronin, Vadim A.
    Usenko, Ganna
    Hajek, Roman
    Benjamin, Reuben
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don A.
    Quach, Hang
    Jagannath, Sundar
    Moreau, Philippe
    Levy, Moshe Y.
    Badros, Ashraf Z.
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Facon, Thierry
    Mateos, Maria-Victoria
    Cavo, Michele
    Chang, Hua
    Landesman, Yosef
    Joshi, Anita A.
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Grosicki, Sebastian
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [42] Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
    Delimpasi, Sosana
    Mateos, Maria Victoria
    Auner, Holger W.
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    Quach, Hang
    Pylypenko, Halyna
    Hajek, Roman
    Leleu, Xavier
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Benjamin, Reuben
    Garg, Mamta Krishnan
    Doronin, Vadim
    Levy, Yair
    Moreau, Philippe
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E83 - E86
  • [43] Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study
    Mateos, Maria
    Jagannath, Sundar
    Delimpasi, Sosana
    Simonova, Maryana
    Spicka, Ivan
    Pour, Ludek
    Kryachok, Irina
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    Pylypenko, Halyna
    Auner, Holger W.
    Leleu, Xavier
    Doronin, Vadim A.
    Usenko, Ganna
    Benjamin, Reuben
    Dolai, Tuphan Kanti
    Sinha, Dinesh Kumar
    Venner, Christopher P.
    Garg, Mamta
    Stevens, Don A.
    Quach, Hang
    Moreau, Philippe
    Levy, Moshe Y.
    Badros, Ashraf Z.
    Anderson, Larry D., Jr.
    Bahlis, Nizar J.
    Facon, Thierry
    Cavo, Michele
    Chai, Yi
    Arazy, Melina
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Richardson, Paul G.
    Grosicki, Sebastian
    BLOOD, 2020, 136
  • [44] Improved patient-reported outcomes with once-weekly insulin icodec with a dosing guide app versus once-daily basal insulin analogues in type 2 diabetes (ONWARDS 5)
    Goldenberg, R.
    Benamar, M.
    Carstensen, L.
    Davies, M.
    Donatsky, A. M.
    Franek, E.
    Kellerer, M.
    Polonsky, W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S397 - S398
  • [45] Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials
    Meletios A. Dimopoulos
    Philippe Moreau
    Shinsuke Iida
    Shang-Yi Huang
    Naoki Takezako
    Wee Joo Chng
    Anita Zahlten-Kumeli
    Martina A. Sersch
    Julia Li
    Mei Huang
    Jae Hoon Lee
    International Journal of Hematology, 2019, 110 : 466 - 473
  • [46] First Report of Disease-specific Patient-reported Outcomes from a Randomized Phase 2 Trial of Once-weekly Somapacitan versus Daily GH in Children with GHD
    Brod, Meryl
    Lee, Kai Woi
    Rasmussen, Michael Hojby
    HORMONE RESEARCH IN PAEDIATRICS, 2020, 93 : 71 - 72
  • [47] Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
    Larocca, Alessandra
    Leleu, Xavier
    Touzeau, Cyrille
    Blade, Joan
    Paner, Agne
    Mateos, Maria-Victoria
    Cavo, Michele
    Maisel, Christopher
    Alegre, Adrian
    Oriol, Albert
    Raptis, Anastasios
    Rodriguez-Otero, Paula
    Mazumder, Amitabha
    Laubach, Jacob
    Nadeem, Omar
    Sandberg, Anna
    Orre, Marie
    Torrang, Anna
    Bakker, Nicolaas A.
    Richardson, Paul G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (03) : 639 - 648
  • [48] Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)
    Mateos, Maria-Victoria
    Ocio, Enrique M.
    Balari, Anna Sureda
    Oriol, Albert
    Garcia, Esther Gonzalez
    Moreno, Maria Jose
    Granell, Miquel
    Escalante, Fernando
    De La Calle, Veronica Gonzalez
    Dachs, Laura Rosinol
    Carrillo-Cruz, Estrella
    Martinez-Lopez, Joaquin
    Sahun, Maria Victoria Dourdil
    Gonzalez, Marta Sonia
    De Oteyza, Jaime Perez
    De Arriba, Felipe
    Hernandez, Miguel T.
    Mateo, Aranzazu Garcia
    Gonzalez, Ana Pilar
    Rios, Rafael
    Cabrera, Carmen
    Bargay, Juan Jose
    Rodriguez-Otero, Paula
    Casado, Felipe
    Casanova, Maria
    Blanchard, Maria Jesus
    Creixenti, Joan Blade
    Lahuerta, Juan Jose
    San-Miguel, Jesus F.
    BLOOD, 2020, 136
  • [49] MLN4924, AN INVESTIGATIONAL NEDD8-ACTIVATING ENZYME (NAE) INHIBITOR, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY LYMPHOMA OR MULTIPLE MYELOMA (MM): PHASE 1 DOSE-ESCALATION STUDY OF TWICE-WEEKLY DOSING
    Harvey, R.
    Lebovic, D.
    Lonial, S.
    Jakubowiak, A.
    Pickard, M.
    McDonald, A.
    Mulligan, G.
    Blakemore, S.
    Kuan, S.
    Dezube, B.
    O'Connor, O.
    HAEMATOLOGICA, 2012, 97 : 432 - 433
  • [50] A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
    Richardson, Paul G.
    Amatangelo, Michael
    Berenson, James R.
    Cerchione, Claudio
    Dimopoulos, Meletios A.
    Hansen, Charlotte Toftmann
    Hwang, Soo Jeong
    Koo, Phillip
    Kuroda, Junya
    Oriol, Albert
    Orlowski, Robert Z.
    Quach, Hang
    Raab, Marc S.
    Rocci, Alberto
    Wang, Yue
    White, Darrell
    Yu, Brian
    Zhou, Zehua
    Katz, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345